Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

References

• Bailey DG, Dresser GK, Leake BF, et al. (2007). Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 81:495–502
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7:248–54
   Web of Science ®Google Scholar
• Cummins CL, Wu CY, Benet LZ. (2002). Sex-related differences in the clearance of cytochrome P450 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474–89
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky LS. (2003). Human extrahepatic cytochrome P450: function of xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tract. Annu Rev Pharmacol Toxicol 43:149–73
   PubMed Web of Science ®Google Scholar
• Domanski TL, He YA, Harlow GR, et al. (2000). Dual role of human cytochrome P450 3A4 resiue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585–91
   PubMed Web of Science ®Google Scholar
• Edwards DJ, Bellevue FH 3rd, Woster PM. (1996). Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 24:1287–90
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33:6–9
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ohta T, Oshima Y, et al. (1997). Specific CYP3A4 inhibitor in grapefruit juice furanocoumarin dimer as components of drug interaction. Pharmacogenetics 7:391–6
   PubMedGoogle Scholar
• Galetin A, Houston JB. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes; impact of prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220–9
   PubMed Web of Science ®Google Scholar
• Giragossian C, LaPerle J, Kosa RE, et al. (2009). Impact of time-dependent inactivation on the estimation of enzyme kinetic parameters for midazolam. Drug Metab Lett 3:45–53
   PubMedGoogle Scholar
• , International Transporter ConsortiumGiacomini KM, Huang SM, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang QY. (2003). The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520–5
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Domanski TL, et al. (2002). Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495–506
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, von Moltke LL, et al. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228–37
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, et al. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96
   PubMed Web of Science ®Google Scholar
• Kuze J, Mutoh T, Takenaka T, et al. (2009). Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 39:871–80
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kim HJ, Miyata M, et al. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309:1282–90
   PubMed Web of Science ®Google Scholar
• Nishimura M, Koeda A, Morikawa H, et al. (2008). Comparison of inducibility of multidrug resistance (MDR)1, multidrug resistance-associated protein (MRP)1, and MRP2 mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Biol Pharm Bull 31:2068–72
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. (2008). Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 23:22–44
   PubMed Web of Science ®Google Scholar
• Nishimura M, Suzuki S, Sato T, et al. (2009). Tissue-specific mRNA expression profiles of human solute carrier 35 transporters. Drug Metab Pharmacokinet 24:91–9
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Beijnen JH, Schellens JH. (2009). The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 35:137–47
   PubMed Web of Science ®Google Scholar
• Paine MF, Widmer WW, Hart HL, et al. (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097–105
   PubMed Web of Science ®Google Scholar
• Paine MF, Widmer WW, Pusek SN, et al. (2008). Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 87:863–71
   PubMed Web of Science ®Google Scholar
• Pal D, Mitra AK. (2006). MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmun Pharmacol 1:323–39
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, et al. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isofrms. J Pharmacol Exp Ther 292:618–28
   PubMed Web of Science ®Google Scholar
• Podoll WF, Kunze KL, Thummel KE, et al. (1995). Evidence supporting mechanism-based inactivation of CYP3A by midazolam. ISSX Proc 8:154
   Google Scholar
• Renaud HJ, Cui JY, Khan M, et al. (2011). Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci 124:261–77
   PubMed Web of Science ®Google Scholar
• Schrag ML, Wienkers LC. (2001). Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 391:49–55
   PubMed Web of Science ®Google Scholar
• Scott EE, Halpert JR. (2005). Structure of cytochrome P450 3A4. Trends Biochem Sci 30:5–7
   PubMed Web of Science ®Google Scholar
• Shin HC, Kim HR, Cho HJ, et al. (2009). Comparative gene expression of intestinal metabolizimg enzymes. Biopharm Drug Dispos 30:411–21
   PubMed Web of Science ®Google Scholar
• Shou M, Dai R, Cui D, et al. (2001). A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256–62
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Rooswinkel RW, Sparidans RW, et al. (2009). Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305–13
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Salphati L, Benet LZ. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89–102
   PubMed Web of Science ®Google Scholar
• Warrington JS, Greenblatt DJ, Moltke LL. (2004). Role of CYP3A enzymes in the biotransformation of triazolam in rat liver. Xenobiotica 34:463–71
   PubMed Web of Science ®Google Scholar
• Won CS, Oberlies NH, Paine MF. (2010). Influence of dietary substances on intestinal drug metabolism and transport. Curr Drug Metab 11:778–92
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, et al. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–108
   PubMed Web of Science ®Google Scholar